Exenatide

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 4669 publications

Adjunctive Treatments for Patients with Type 1 Diabetes Using Automated Insulin Delivery Systems. A Narrative Review.

Adjunctive Treatments for Patients with Type 1 Diabetes Using Automated Insulin Delivery Systems. A Narrative Review.

Journal: Diabetes technology & therapeutics

Published: September 04, 2026

Influence of GLP-1 Receptor Agonists on Surgical and Nonsurgical Treatment of Ankle Osteoarthritis.

Influence of GLP-1 Receptor Agonists on Surgical and Nonsurgical Treatment of Ankle Osteoarthritis.

Journal: Foot & ankle specialist

Published: August 18, 2026

Glucagon-like Peptide-1 Receptor Agonist-Associated Injection Site and Dermatologic Reactions.

Glucagon-like Peptide-1 Receptor Agonist-Associated Injection Site and Dermatologic Reactions.

Journal: Clinics in dermatology

Published: August 14, 2026

PT320, a GLP-1 receptor agonist, mitigates nucleus accumbens-associated depression- and anxiety-like behaviors in MitoPark mice of Parkinson's disease.

PT320, a GLP-1 receptor agonist, mitigates nucleus accumbens-associated depression- and anxiety-like behaviors in MitoPark mice of Parkinson's disease.

Journal: Journal of Parkinson's disease

Published: August 12, 2026

Glucagon-like peptide-1 receptor agonist-based regimens compared with metformin-based regimens for preventing cardiovascular disease in adults with type 2 diabetes mellitus.

Glucagon-like peptide-1 receptor agonist-based regimens compared with metformin-based regimens for preventing cardiovascular disease in adults with type 2 diabetes mellitus.

Journal: The Cochrane database of systematic reviews

Published: August 10, 2026

Surgery on Patients Taking Glucagon-Like Peptide-1 Receptor Agonists.

Surgery on Patients Taking Glucagon-Like Peptide-1 Receptor Agonists.

Journal: Advances in surgery

Published: August 05, 2026

Effects of GLP-1 Receptor Agonist Exenatide on Mitochondrial Dysfunction After Spinal Cord Injury.

Effects of GLP-1 Receptor Agonist Exenatide on Mitochondrial Dysfunction After Spinal Cord Injury.

Journal: Neurotrauma reports

Published: August 01, 2026

Incretin-based therapies, alcohol and tobacco use, and acute substance-related events: emerging implications for cardiovascular medicine.

Incretin-based therapies, alcohol and tobacco use, and acute substance-related events: emerging implications for cardiovascular medicine.

Journal: Journal of cardiovascular pharmacology

Published: July 28, 2026

Postmarketing Safety Signals and Medication-Use Risks of GLP-1-Based Therapies in Diabetes and Obesity: A Multi-Source Pharmacovigilance and Regulatory Evidence-Mapping Study.

Postmarketing Safety Signals and Medication-Use Risks of GLP-1-Based Therapies in Diabetes and Obesity: A Multi-Source Pharmacovigilance and Regulatory Evidence-Mapping Study.

Journal: Diabetes, obesity & metabolism

Published: July 14, 2026

GLP-1 Receptor Agonists and Fertility: What Is Known So Far?

GLP-1 Receptor Agonists and Fertility: What Is Known So Far?

Journal: JBRA assisted reproduction

Published: July 13, 2026

Comparative Effectiveness of Glucagon-like Peptide-1 Receptor Agonists Versus Oral Agents for Insulin Discontinuation in Type 2 Diabetes : A Target Trial Emulation.

Comparative Effectiveness of Glucagon-like Peptide-1 Receptor Agonists Versus Oral Agents for Insulin Discontinuation in Type 2 Diabetes : A Target Trial Emulation.

Journal: Annals of internal medicine

Published: July 13, 2026

M4 drug discovery: Human drug predictions from integrated preclinical insights exemplified with a GLP-1R agonist.

M4 drug discovery: Human drug predictions from integrated preclinical insights exemplified with a GLP-1R agonist.

Journal: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences

Published: July 10, 2026

Showing 1-12 of 4,669

Last Updated: 09/26/2026